The heterogeneity of breast cancer subtypes complicates treatment outcomes, particularly for human epidermal growth factor receptor 2 (HER2)-positive breast cancers, which account for 14% of cases and are associated with a poor prognosis [3]. The gene discussed is ERBB2; the disease is breast carcinoma.